Mostrando postagens com marcador câncer. Mostrar todas as postagens
Mostrando postagens com marcador câncer. Mostrar todas as postagens

sábado, 23 de agosto de 2008

Diabetes e Linfoma

American Journal of Epidemiology 2008 168(5):471-480; doi:10.1093/aje/kwn160
Type 2 Diabetes Mellitus and Risk of Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.
(e-mail: chun.r.chao@kp.org)
for publication February 19, 2008. Accepted for publication May 8, 2008.
Type 2 diabetes mellitus is associated with altered immune function and chronic inflammation. Both of these immune conditions are implicated in the pathogenesis of non-Hodgkin lymphoma. The authors performed a systematic review to summarize findings from the current literature on the association between history of type 2 diabetes mellitus and risk of non-Hodgkin lymphoma. Ten case-control studies and three prospective cohort studies were included in this review. Meta-analysis found that a history of type 2 diabetes mellitus was positively associated with overall non-Hodgkin lymphoma risk. However, there was significant heterogeneity between studies. Study design was an important source of heterogeneity. The rate ratio between type 2 diabetes mellitus and non-Hodgkin lymphoma was found to be 1.18 (95% confidence interval: 0.99, 1.42) among case-control studies and 1.79 (95% confidence interval: 1.30, 2.47) among the prospective cohort studies. Weaknesses were identified in some of the included studies in the areas of case and control selection, measurement of covariates and non-Hodgkin lymphoma, and confounding control. Although a positive association between type 2 diabetes mellitus and risk of non-Hodgkin lymphoma was suggested, the evidence is inconclusive because of methodological limitations of the included case-control studies. More prospective studies with improved control of confounding are needed to confirm these findings.
diabetes mellitus; diabetes mellitus, type 2; lymphoma; lymphoma, non-Hodgkin; meta-analysis

terça-feira, 12 de agosto de 2008

Vitamina D e Mortalidade: NHANES III

25-Hydroxyvitamin D Levels and the Risk of Mortality in the General Population
Michal L. Melamed, MD, MHS; Erin D. Michos, MD, MHS; Wendy Post, MD, MS; Brad Astor, PhD
Arch Intern Med. 2008;168(15):1629-1637.
Background In patients undergoing dialysis, therapy with calcitriol or paricalcitol or other vitamin D agents is associated with reduced mortality. Observational data suggests that low 25-hydroxyvitamin D levels (25[OH]D) are associated with diabetes mellitus, hypertension, and cancers. However, whether low serum 25(OH)D levels are associated with mortality in the general population is unknown.
Methods We tested the association of low 25(OH)D levels with all-cause, cancer, and cardiovascular disease (CVD) mortality in 13 331 nationally representative adults 20 years or older from the Third National Health and Nutrition Examination Survey (NHANES III) linked mortality files. Participant vitamin D levels were collected from 1988 through 1994, and individuals were passively followed for mortality through 2000.
Results In cross-sectional multivariate analyses, increasing age, female sex, nonwhite race/ethnicity, diabetes, current smoking, and higher body mass index were all independently associated with higher odds of 25(OH)D deficiency (lowest quartile of 25(OH)D level, <17.8>

domingo, 27 de julho de 2008

PSA: nova revisão sistemática

Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force.
Annals of Internal Medicine Volume 149(3) August 5, 2008
Background: Prostate cancer is the most common nonskin cancer in men in the United States, and prostate cancer screening has increased in recent years. In 2002, the U.S. Preventive Services Task Force concluded that evidence was insufficient to recommend for or against screening for prostate cancer with prostate-specific antigen (PSA) testing.Purpose: To examine new evidence on benefits and harms of screening asymptomatic men for prostate cancer with PSA.Data Sources: English-language articles identified in PubMed and the Cochrane Library (search dates, January 2002 to July 2007), reference lists of retrieved articles, and expert suggestions.Study Selection: Randomized, controlled trials and meta-analyses of PSA screening and cross-sectional and cohort studies of screening harms and of the natural history of screening-detected cancer were selected to answer the following questions: Does screening for prostate cancer with PSA, as a single-threshold test or as a function of multiple tests over time, decrease morbidity or mortality? What are the magnitude and nature of harms associated with prostate cancer screening, other than overtreatment? What is the natural history of PSA-detected, nonpalpable, localized prostate cancer?Data Extraction: Studies were reviewed, abstracted, and rated for quality by using predefined U.S. Preventive Services Task Force criteria.Data Synthesis: No good-quality randomized, controlled trials of screening for prostate cancer have been completed. In 1 cross-sectional and 2 prospective cohort studies of fair to good quality, false-positive PSA screening results caused psychological adverse effects for up to 1 year after the test. The natural history of PSA-detected prostate cancer is poorly understood.Limitations: Few eligible studies were identified. Long-term adverse effects of false-positive PSA screening test results are unknown.Conclusion: Prostate-specific antigen screening is associated with psychological harms, and its potential benefits remain uncertain

Padrões de dieta e Mortalidade: Nurses´Health Study

Dietary Patterns and Risk of Mortality From Cardiovascular Disease, Cancer, and All Causes in a Prospective Cohort of Women. Christin Heidemann, DrPH, MSc; Matthias B. Schulze, DrPH; Oscar H. Franco, MD, DSc, PhD; Rob M. van Dam, PhD; Christos S. Mantzoros, MD, DSc; Frank B. Hu, MD, PhD Circulation. 2008;118:230-237
Background— The impact of overall dietary patterns that reflect actual eating behaviors on mortality caused by cardiovascular or other chronic diseases is largely unknown.
Methods and Results— We prospectively evaluated the relation between dietary patterns and risk of cardiovascular, cancer, and all-cause mortality among 72 113 women who were free of myocardial infarction, angina, coronary artery surgery, stroke, diabetes mellitus, or cancer and were followed up from 1984 to 2002. Dietary patterns were derived by factor analysis based on validated food frequency questionnaires administered every 2 to 4 years. Two major dietary patterns were identified: High prudent pattern scores represented high intakes of vegetables, fruit, legumes, fish, poultry, and whole grains, whereas high Western pattern scores reflected high intakes of red meat, processed meat, refined grains, french fries, and sweets/desserts. During 18 years of follow-up, 6011 deaths occurred, including 1154 cardiovascular deaths and 3139 cancer deaths. After multivariable adjustment, the prudent diet was associated with a 28% lower risk of cardiovascular mortality (95% confidence interval [CI], 13 to 40) and a 17% lower risk of all-cause mortality (95% CI, 10 to 24) when the highest quintile was compared with the lowest quintile. In contrast, the Western pattern was associated with a higher risk of mortality from cardiovascular disease (22%; 95% CI, 1 to 48), cancer (16%; 95% CI, 3 to 30), and all causes (21%; 95% CI, 12 to 32).
Conclusion— Greater adherence to the prudent pattern may reduce the risk of cardiovascular and total mortality, whereas greater adherence to the Western pattern may increase the risk among initially healthy women.

sexta-feira, 6 de abril de 2007

Rio Grande do Sul: as maiores taxas de câncer de pulmão.

C0m a Souza Cruz recebendo apoio total da Governadora Yeda Crusius e do Movimento dos Sem Terra, o Rio Grande do Sul está quase unido na defesa incondicional do câncer de pulmão. Apresento acima, as taxas de mortalidade por câncer de pulmão e de laringe por estados brasileiros. A região sul desponta com o Rio Grande do Sul (primeiro), Santa Catarina (segundo) e Paraná (quarto). O "quase unido" da frase acima foi para saudar a luta dos médicos gaúchos contra o tabagismo, na figura de Mário Rigatto (1928-2000), um dos pais da pneumologia brasileira.
observação: as taxas em 100.000 por habitantes foram calculados em base do informado no site do Datasus no ano de 2004 para as faixa etária 45-74 anos para ambos os sexos.

quinta-feira, 15 de março de 2007

Wall Street e o preço dos medicamentos

Não se origina de ninguém do governo, de ONGs, de partidos políticos, mas sim do próprio centro financeiro americano o questionamento do preço elevado dos medicamentos novos para tratamento para o câncer. Ruim, para os negócios concluiu o analista da Morgan Stanley.
From Wall Street, a WarningAbout Cancer-Drug Prices
Morgan Stanley AnalystCreates Stir in IndustryAs He Sees a Backlash
By GEETA ANANDMarch 15, 2007; Page A1
Two years ago, Steven Harr urged
Genentech Inc. to lower the price of a key drug that was helping buoy its stock price. He was an unlikely messenger because of his job: a Wall Street research analyst whose investing clients crave profits.
In a conference room with 30 senior managers from the biotech company, Dr. Harr said he feared patients wouldn't be able to afford the drug Avastin, which costs about $47,000 for the average 10-month course of treatment for colorectal cancer. He warned that Congress "will get involved when its constituents can't get drugs." Genentech later capped Avastin's price, acknowledging the influence of Dr. Harr, among many others.
From his perch at
Morgan Stanley, the 36-year-old Dr. Harr has become an important gadfly on the most controversial issue in the biotech industry: drug pricing. A burst of expensive new drugs -- routinely costing tens of thousands of dollars a year -- is boosting the fortunes of biotech companies, which say the prices reward investors, reflect the difficulty of developing these medicines and fuel vital research. But the costs are setting off a growing outcry from patient advocates, doctors and Congress, which is considering two bills aiming to bring prices down. Wall Street analysts rarely speak out for fear of alienating the companies they cover. But as Dr. Harr sees it, the high costs are bad for business. He has repeatedly argued that rising drug prices could trigger government controls, hurting the industry long term. He says soaring cancer-drug prices, generating fat profit margins, aren't sustainable.
"I do not favor government setting prices on drugs because it will stymie innovation," he says, "but it is my fear that this will happen."
Advances in research are changing cancer from a death sentence to a chronic disease for many people. That is also bringing huge new costs:
In 2002, cancer drugs accounted for 13% of the nation's drug spending, according to Morgan Stanley; this year it says such spending is projected to almost double, to 22%. For now, the high prices of cancer drugs are continuing to boost the stocks of companies that make them. Indeed, investors who followed Dr. Harr's advice on Genentech stock would have missed out on a 25% surge in the two years he urged caution on the shares.
Propelled by sales of expensive new drugs, Genentech, based in South San Francisco, Calif., is one of the world's fastest-growing companies. It reported revenue of $9.3 billion in 2006, a 40% increase from 2005. Net income rose 64% in 2006 to $2.1 billion.
But a pushback on drug prices is gathering steam in the Democrat-controlled Congress. And already, the two biggest biotechs, Genentech and
Amgen Inc., have taken initiatives to cap prices of certain cancer drugs.
Dr. Harr "pointed out a potential risk that wasn't completely understood by everyone," says Jay Markowitz, a surgeon and now a biotechnology analyst at mutual-fund company T. Rowe Price Group.
"What he said was relevant and it was necessary, but it was not a popular thought," adds Bill Slattery, a partner at Deerfield Partners, a New York health-care investment fund that has invested in Genentech.
Dr. Harr grew up in Omaha, Neb., the second of four children of an attorney and a journalist. Conversations at the family dinner table were often debates on issues of the day; because of his strong opinions, his father sarcastically dubbed him "the diplomat."
After graduating from Johns Hopkins School of Medicine, Dr. Harr was finishing his residency at the University of California, San Francisco, when he grew interested in biotechnology. In 2000, instead of beginning a cardiology fellowship, he headed to Wall Street. He followed a friend to the former boutique investment bank Robertson Stephens, which hired him as a junior analyst. Two years later, he moved to Morgan Stanley.
Cancer-drug prices moved to a new level of the stratosphere in 2004, when two products came to market at huge premiums over others in the field. Erbitux, made by
ImClone Systems Inc. and partner Bristol-Myers Squibb Co., was introduced at $10,000 a month. That was about $40,000 for the course of treatment for the average late-stage colorectal-cancer patient for whom it was marketed.
The price shocked Dr. Harr. Biotech drugs, which are produced by live cells, were generally more expensive than pills that are a mixture of chemicals. But this was twice the price of other new cancer drugs on the market, and many times the cost of older drugs
.

domingo, 11 de fevereiro de 2007

A indústria dos protetores solares agradecem ao IUV.

A Folha de S.Paulo (11/02/06) informa que publicará diariamente o índice de radiação ultra-violeta (IUV) na secção de metereologia, tal como ocorre na maioria dos jornais do mundo. Tudo bem, teremos uma informação a mais para nos preocupar, junto com o fantasioso "risco-país".
Esse IUV irá estimular ainda mais a indústria da proteção da luz solar como os fabricantes de protetores de luz solar.
Pobre astro-rei! Fundamental para a vida no Planeta, agora é acusado de causar doenças. A relação entre irradiação solar e câncer de pele (não-melanoma) de letalidade baixa é decorrente do tempo de exposição e, não da intensidade. Ou seja, o problema é muito maior para o trabalhador do campo e da cidade expostos todos os dias do que para crianças e jovens mimados que se lambuzam de protetores solares em breves períodos do ano. Lembro que os "protetores não protegem" do melanoma, um câncer com letalidade alta.